Researchers have found that alteration in the environment and atomospheric factors could be associated with organ specific flare-ups of lupus among patients diagnosed with Systemic Lupus Erythematosus (SLE). The study results were presented at the 2019 ACR/ARP Annual Meeting. The abstract was titled, “Environmental and Atmospheric Factors in Systemic Lupus Erythematosus: A Regression Analysis.”
The researchers explained that SLE is a chronic condition that leads to inflammation which may affect various organs within the body including skin and the joints. Kidneys, lungs and even the brain and the heart can be affected by SLE. Non-specific symptoms including fever, fatigue or lethargy, weight loss etc. are common features of the conditions.
Few AIM-listed drug development companies have late-stage clinical assets in the pipeline, ImmuPharma plc (LON:IMM) is an exception. The Company’s lead compound, Lupuzor™, a potential treatment for Lupus, has completed Phase 3 trial of dosing patients across the US, Europe and Mauritius with top line results announced.